Lobe Sciences logo

Lobe Sciences(OTC) LOBEF

Market Cap$10.47MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-93%
5 Year-87%
1 Year+13%
1 Month-36%
$0.03
+2.41%
+0.00Today
Lobe Sciences last closing stock price
MetricPriceDate
Last closeUSD 0.032026-10-19
Lobe Sciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-23.16%USD 0.042026-10-12
1 month-36.37%USD 0.052026-09-18
3 month-52.67%USD 0.072026-07-21
Year to date-1.22%USD 0.032025-12-31
1 year+13.27%USD 0.032025-10-17
3 year+134.34%USD 0.012023-10-20
5 year-87.41%USD 0.272021-10-20
Since inception-92.92%USD 0.482019-10-04

Lobe Sciences Financials at a Glance

Market Cap

$10.47MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$0.00

Net Income (TTM)

-CA$5.17M

EPS (TTM)

-$0.02

P/E Ratio

-2.27

Dividend

$0.00

Beta (Volatility)

0.34 (Low)

Price

$0.03

Volume

100

Open

$0.03

Previous Close

$0.03

Daily Range

$0.03 - $0.03

52-Week Range

$0.02 - $0.11

Estimated Earnings Date

Dec 28, 2026

LOBEF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Lobe Sciences

Lobe Sciences Ltd. is a life sciences company dedicated to researching and developing psychedelic-based medicines. The company focuses on psilocybin-derived treatments combined with N-acetylcysteine, targeting mild traumatic brain injuries (mTBI) and post-traumatic stress disorder (PTSD).

Products and Services
  • Psilocybin-derived treatments for mTBI and PTSD
  • Combination therapies with N-acetylcysteine
  • Specialized devices for drug administration efficiency
Growth Outlook
  • Expanding research into psychedelic therapies aligns with increasing market demand
  • Recent name change reflects a strategic focus on innovative treatments
  • Strong cash position supports ongoing research and development initiatives
Financial Highlights
  • Recent quarterly net income of -$529,936 indicates ongoing investment in R&D
  • Cash and short-term investments totaled $5,210,418, providing operational flexibility
  • Trailing twelve months (TTM) cash flow metrics show a focus on growth despite losses
Lobe Sciences Ltd. operates in the burgeoning biotechnology sector, specifically targeting mental health conditions through innovative therapies. The company's commitment to developing psilocybin-based treatments positions it well within a rapidly evolving market. The recent financial data indicates a focus on research and development, with significant investments aimed at advancing therapeutic solutions. The strong cash position allows for continued exploration of new treatment avenues, which may attract interest from investors looking for opportunities in the life sciences field.
AI Generated • Oct 3, 2026

Industry

Pharmaceuticals

Sector

Health Care

CEO

Frederick D. Sancilio, PhD

Website

www.lobesciences.com

Headquarters

Vancouver, BC V6G 3B7, CA

LOBEF Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-338.76%

Return on Capital

-158.97%

Return on Assets

-93.41%

Earnings Yield

-44.05%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$10.47MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

308.18M

Volume

100

Avg. Volume

65.63K

Financials (TTM)

Gross Profit

CA$0.00

Operating Income

-CA$6.86M

EBITDA

-CA$6.85M

Operating Cash Flow

-CA$3.74M

Capital Expenditure

-CA$4.00

Free Cash Flow

-CA$3.74M

Cash & ST Invst.

CA$5.21M

Total Debt

CA$338.62K

Lobe Sciences Performance Analysis

Lobe Sciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-08-31CAD 0N/A
20232023-08-31CAD 624,146N/A
20242024-08-31CAD 100,098-84.0%
20252025-08-31CAD 0N/A
Lobe Sciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-08-31N/A
Q12025-11-30N/A
Q22026-02-28N/A
Q32026-05-31N/A
Lobe Sciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-08-31CAD -0.25N/A
20232023-08-31CAD -0.03-86.8%
20242024-08-31CAD -0.03-20.6%
20252025-08-31CAD -0.02-13.9%
Lobe Sciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-08-31-70.6%
Q12025-11-3060.9%
Q22026-02-28-94.1%
Q32026-05-3171.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2026YOY CHG

Revenue

CA$0.00

N/A

Gross Profit

CA$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$10.47MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

0

N/A

Net Income

-CA$529.94K

+46.2%

EBITDA

-CA$1.18M

-21.1%

Quarterly Fundamentals

Name
Q3 2026YOY CHG

Total Cash

CA$5.21M

-34.6%

Total Debt

CA$338.62K

-86.3%

Accounts Receivable

CA$8.91K

+85.0%

Inventory

CA$0.00

N/A

Long Term Debt

CA$0.00

-100.0%

Short Term Debt

CA$338.62K

-47.2%

Return on Assets

-93.41%

N/A

Return on Invested Capital

-2.14%

N/A

Free Cash Flow

-CA$707.93K

-73.4%

Operating Cash Flow

-CA$707.92K

-73.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,704.21+0.01%
^DJIDJI
$52,064.30+0.00%
^IXICNASDAQ
$26,465.53+0.01%
BTCBitcoin
$81,947.00+0.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$98.65+5.32%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$46.63-5.28%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$37.52-3.55%
TQQQProShares Trust - ProShares UltraPro Qqq
$70.64+3.56%

Questions About LOBEF

What is the current price of Lobe Sciences?

Lobe Sciences is trading at $0.03 per share.

What is the 52-week range for Lobe Sciences?

Over the past 52 weeks, Lobe Sciences has traded between $0.02 and $0.11.

How much debt does Lobe Sciences have?

As of the most recent reporting period, Lobe Sciences reported total debt of CA$245.65K.

How much cash does Lobe Sciences have on hand?

Lobe Sciences reported CA$1.09M in cash and cash equivalents in its most recent financial results.

What is Lobe Sciences’s dividend yield?

Lobe Sciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services